Th17 cell responses in spondyloarthritis

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Interleukin-17 (IL-17) plays a crucial role in inflammatory processes, particularly in spondyloarthritis (SpA).
• The discovery and properties of IL-17 have identified it as a significant therapeutic target for arthritis.
• IL-17 is vital for immune defense against fungal infections and maintaining gut epithelial barrier function.

Purpose of the Study:

• To review the discovery, properties, and inflammatory roles of IL-17 in the context of spondyloarthritis (SpA).
• To explore the regulation of IL-17-producing cells, including Th17 CD4+ T cells and the role of IL-23.
• To discuss potential adverse effects of IL-17 blockade and review current evidence for its use in SpA.

Main Methods:

• Literature review of the discovery and biological properties of IL-17.
• Analysis of research on the differentiation of IL-17-producing cells (Th17 CD4+ T cells) and IL-23.
• Review of current clinical evidence for IL-17 blockade in various forms of SpA.

Main Results:

• IL-17 is implicated in the pathogenesis of SpA, making it an attractive therapeutic target.
• Understanding Th17 cell differentiation and IL-23 pathways offers alternative therapeutic strategies.
• IL-17 blockade may have adverse effects related to its role in infection defense and barrier function.

Conclusions:

• Targeting IL-17 is an established and effective treatment strategy for spondyloarthritis (SpA).
• Further research into IL-17 regulation may yield alternative therapies.
• The benefits of IL-17 blockade in SpA must be weighed against potential risks associated with its physiological roles.